Pracinostat

Shareholder Alert: Robbins LLP Reminds Investors MEI Pharma, Inc. (MEIP) Accused of Misleading Shareholders

Retrieved on: 
Friday, October 23, 2020
Legal, Professional services, Benzimidazoles, Pracinostat, Protein deacetylase, Histone deacetylase

Shareholder rights law firm Robbins LLP reminds investors that a purchaser of MEI Pharma, Inc. (NASDAQ: MEIP) filed a class action complaint against the Company for alleged violations of the Securities Exchange Act of 1934 between August 2, 2017 and July 1, 2020.

Key Points: 
  • Shareholder rights law firm Robbins LLP reminds investors that a purchaser of MEI Pharma, Inc. (NASDAQ: MEIP) filed a class action complaint against the Company for alleged violations of the Securities Exchange Act of 1934 between August 2, 2017 and July 1, 2020.
  • MEI Pharma is a late-stage pharmaceutical company that focuses on the development of various therapies for the treatment of cancer.
  • One of MEI Pharma's drug candidates include Pracinostat, an oral histone deacetylase (HDAC) inhibitor.
  • On this news, MEI Pharma's shares fell 18% to close at $3.49 per share and has yet to recover.

DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against MEI Pharma, Inc. and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, October 1, 2020
Hydroxamic acids, Benzimidazoles, Pracinostat, Drugs, Branches of biology, Antineoplastic drugs, Chemistry, Histone deacetylase, Epigenetics, Orphan drugs, TopoTarget, Romidepsin

Investors have until October 9, 2020 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until October 9, 2020 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • MEI Pharma is a late-stage pharmaceutical company that focuses on the development of various therapies for the treatment of cancer.
  • MEI Pharmas clinical drug candidates include, among others, Pracinostat, an oral histone deacetylase (HDAC) inhibitor.
  • On July 2, 2020, MEI Pharma issued a press release announcing that it was discontinuing the Phase 3 Pracinostat Trial.

Shareholder Alert: Robbins LLP Announces MEI Pharma, Inc. (MEIP) Accused of Misleading Shareholders

Retrieved on: 
Wednesday, August 12, 2020
Legal, Professional services, Hydroxamic acids, Benzimidazoles, Pracinostat, Histone deacetylase, Antineoplastic drugs, Orphan drugs

MEI Pharma is a late-stage pharmaceutical company that focuses on the development of various therapies for the treatment of cancer.

Key Points: 
  • MEI Pharma is a late-stage pharmaceutical company that focuses on the development of various therapies for the treatment of cancer.
  • One of MEI Pharma's drug candidates is Pracinostat, an oral histone deacetylase (HDAC) inhibitor.
  • If you suffered a loss as a result of MEI Pharma's misconduct, click here .
  • In later SEC reports and filings, MEI Pharma continued to tout the "potency" and median overall survival of patients in the Phase 2 trial of Pracinostat.

MEI PHARMA ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against MEI Pharma, Inc. and Encourages Investors to Contact the Firm

Retrieved on: 
Tuesday, August 11, 2020
Legal, Professional services, Hydroxamic acids, Benzimidazoles, Pracinostat, Drugs, Branches of biology, Antineoplastic drugs, Chemistry, Histone deacetylase, Epigenetics, Orphan drugs, TopoTarget, Romidepsin

Investors have until October 9, 2020 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until October 9, 2020 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • MEI Pharma is a late-stage pharmaceutical company that focuses on the development of various therapies for the treatment of cancer.
  • MEI Pharmas clinical drug candidates include, among others, Pracinostat, an oral histone deacetylase (HDAC) inhibitor.
  • On July 2, 2020, MEI Pharma issued a press release announcing that it was discontinuing the Phase 3 Pracinostat Trial.

Growth of HDAC (Histone Deacetylase) Inhibitors Market to be Impacted by Increasing Awareness About Cancer | Technavio

Retrieved on: 
Friday, October 18, 2019
Biotechnology, Pharmaceutical, Health, Oncology, Antineoplastic drugs, Histone deacetylase inhibitor, Drugs, Histone deacetylase, Clinical medicine, Branches of biology, Hydroxamic acids, Protein deacetylase, Orphan drugs, Romidepsin, Pracinostat

HDAC (histone deacetylase) Inhibitors Market Landscape 2019-2023: Geographic landscape

Key Points: 
  • HDAC (histone deacetylase) Inhibitors Market Landscape 2019-2023: Geographic landscape
    HDAC (histone deacetylase) Inhibitors Market Landscape 2019-2023: RoA
    Register for a free trial today and gain instant access to 10,000+ market research reports.
  • HDAC inhibitors demonstrate promising results in cancer treatments and can induce apoptosis, cell-cycle arrest, and differentiation.
  • As a result, strong research will help in quick launch of these target-specific HDAC molecules and drive the market.
  • This improves the adherence of patients toward treatment regimen, which in turn, will boost the demand for HDAC (histone deacetylase) inhibitors.

Global HDAC (histone deacetylase) Inhibitors Market to 2023 Featuring Celgene, Merck & Co, Novartis, Shenzhen Chipscreen Biosciences, & Spectrum Pharmaceuticals

Retrieved on: 
Friday, April 26, 2019
Antineoplastic drugs, Histone deacetylase inhibitor, Histone deacetylase, Hydroxamic acids, Epigenetics, Pracinostat, Epigenetics of cocaine addiction

The HDAC (histone deacetylase) inhibitors market will register a CAGR of nearly 7% by 2023.

Key Points: 
  • The HDAC (histone deacetylase) inhibitors market will register a CAGR of nearly 7% by 2023.
  • The development of novel drug delivery systems and combination therapies will drive the HDAC inhibitors market growth during the forecast period.
  • One of the growth drivers of the global HDAC (histone deacetylase) inhibitors market is the high prevalence of oncology indications.
  • One of the challenges in the growth of the global HDAC (histone deacetylase) inhibitors market is the high costs associated with treatment.

Global HDAC (histone deacetylase) Inhibitors Market 2019-2023 - High Prevalence of Oncology Indications / High Costs Associated with Treatment - ResearchAndMarkets.com

Retrieved on: 
Thursday, April 25, 2019
Health, Oncology, Pharmaceutical, Branches of biology, Histone deacetylase inhibitor, Histone deacetylase, Epigenetics, Hydroxamic acids, Psychoactive drugs, Clinical medicine, Pracinostat, Epigenetics of cocaine addiction

The development of novel drug delivery systems and combination therapies will drive the HDAC inhibitors market growth during the forecast period.

Key Points: 
  • The development of novel drug delivery systems and combination therapies will drive the HDAC inhibitors market growth during the forecast period.
  • One of the growth drivers of the global HDAC (histone deacetylase) inhibitors market is the high prevalence of oncology indications.
  • One of the challenges in the growth of the global HDAC (histone deacetylase) inhibitors market is the high costs associated with treatment.
  • The high treatment costs act as a barrier for drug adoption, which reduces the patient base and poses a challenge to market growth.

The HDAC (histone deacetylase) inhibitors market will register a CAGR of nearly 7% by 2023

Retrieved on: 
Thursday, April 18, 2019
Antineoplastic drugs, Histone deacetylase inhibitor, Histone deacetylase, Hydroxamic acids, Epigenetics, Pracinostat, Epigenetics of cocaine addiction

The development of novel drug delivery systems and combination therapies will drive the HDAC inhibitors market growth during the forecast period.

Key Points: 
  • The development of novel drug delivery systems and combination therapies will drive the HDAC inhibitors market growth during the forecast period.
  • Analysts have predicted that the HDAC (histone deacetylase) inhibitors market will register a CAGR of nearly 7% by 2023.
  • One of the growth drivers of the global HDAC (histone deacetylase) inhibitors market is the high prevalence of oncology indications.
  • One of the challenges in the growth of the global HDAC (histone deacetylase) inhibitors market is the high costs associated with treatment.

MEI Pharma to Present Clinical Data from Three Oncology Programs at the 2018 American Society of Hematology (ASH) Annual Meeting

Retrieved on: 
Thursday, November 1, 2018
Benzimidazoles, Pracinostat

"Data reported at the ASH Annual Meeting this year continue to highlight the depth of our clinical pipeline and the progress across multiple programs, each with its own distinct mechanisms for targeting cancer biology," saidDaniel P. Gold, Ph.D., president and chief executive officer of MEI Pharma.

Key Points: 
  • "Data reported at the ASH Annual Meeting this year continue to highlight the depth of our clinical pipeline and the progress across multiple programs, each with its own distinct mechanisms for targeting cancer biology," saidDaniel P. Gold, Ph.D., president and chief executive officer of MEI Pharma.
  • These results are supportive of possible future studies evaluating voruciclib in combination with venetoclax in relapsed AML."
  • The Company's portfolio of drug candidates includes pracinostat, an oral HDAC inhibitor that is partnered with Helsinn Healthcare, SA.
  • We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.

MEI Pharma to Release 2018 Fiscal Year End Financial Results and Provide Corporate Update on August 30, 2018

Retrieved on: 
Thursday, August 23, 2018
Benzimidazoles, Pracinostat

The Company will host a conference call and live webcast with the investment community to provide a corporate update the same day at5:00 p.m.

Key Points: 
  • The Company will host a conference call and live webcast with the investment community to provide a corporate update the same day at5:00 p.m.
  • MEI Pharma, Inc. (Nasdaq: MEIP) is aSan Diego-based pharmaceutical company focused on leveraging its extensive development and oncology expertise to identify and advance new therapies for cancer.
  • The Company's portfolio of drug candidates includes pracinostat, an oral HDAC inhibitor that is partnered with Helsinn Healthcare, SA.
  • We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.